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Signaling pathway splicing. <p>A systematic analysis of the FANTOM3 mouse cDNA dataset provides transcriptional evidence of widespread alternate splicing in the  Toll-like receptor signaling pathway.</p>
Abstract
Background: Alternate splicing of key signaling molecules in the Toll-like receptor (Tlr) cascade
has been shown to dramatically alter the signaling capacity of inflammatory cells, but it is not known
how common this mechanism is. We provide transcriptional evidence of widespread alternate
splicing in the Toll-like receptor signaling pathway, derived from a systematic analysis of the
FANTOM3 mouse data set. Functional annotation of variant proteins was assessed in light of
inflammatory signaling in mouse primary macrophages, and the expression of each variant
transcript was assessed by splicing arrays.
Results: A total of 256 variant transcripts were identified, including novel variants of Tlr4, Ticam1,
Tollip, Rac1, Irak1, 2 and 4, Mapk14/p38, Atf2 and Stat1. The expression of variant transcripts was
assessed using custom-designed splicing arrays. We functionally tested the expression of Tlr4
transcripts under a range of cytokine conditions via northern and quantitative real-time polymerase
chain reaction. The effects of variant Mapk14/p38 protein expression on macrophage survival were
demonstrated.
Conclusion: Members of the Toll-like receptor signaling pathway are highly alternatively spliced,
producing a large number of novel proteins with the potential to functionally alter inflammatory
outcomes. These variants are expressed in primary mouse macrophages in response to
inflammatory mediators such as interferon-γ and lipopolysaccharide. Our data suggest a surprisingly
common role for variant proteins in diversification/repression of inflammatory signaling.
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Background
Infectious diseases have exerted enormous pressures on
mammalian populations; this can be observed in the way in
which innate immune systems have evolved to recognize a
vast and rapidly changeable pathogen world. An effective
innate immune system must not be restricted to the recogni-
tion of individual disease agents, but rather the molecular
patterns associated with different classes of pathogens (path-
ogen-associated molecular patterns (PAMPs)), hence the evo-
lution of pattern recognition receptors [1]. These receptor
complexes are characteristically large, multimeric and poly-
morphic in the extracellular domains, and signal through
highly conserved pathways to induce an acute inflammatory
response.
The Toll-like receptors (Tlrs) are a highly evolutionarily con-
served family of pattern recognition receptors, consisting of
at least 13 members that are central to the recognition of a
large collection of PAMPs (for review, see [2]). Tlr members
have variable leucine-rich repeat extracellular domains and a
characteristic toll-interleukin receptor (TIR) intracellular
domain that signals through the highly conserved myeloid
differentiation primary-response gene 88 (Myd88)/IL-1
receptor associated kinase (Irak)/tumor necrosis factor
(TNF) receptor-associated factor-6/nuclear factor-κB cas-
cade [3,4]. Mutations in various Tlrs have been clinically
associated with susceptibility to infectious diseases, and Tlr
members have been linked to chronic inflammatory diseases
such as arteriosclerosis, periodontal diseases, arthritis, and
lung disease (for review, see [5]). Pattern recognition recep-
tors such as the Tlr family are essential for the rapid recogni-
tion of pathogens; equally important is an appropriate
inflammatory response, central to which is the resolution of
that inflammatory cascade (for review, see [6]).
A diverse repertoire of innate immune responses is vital to the
survival of a population threatened by infectious disease, and
those pathogens that exploit stereotyped host responses are
among the most clinically devastating [7]. The high degree of
signaling conservation within the TIR superfamily of recep-
tors, even across phyla, may seem counter-intuitive, given the
drive to diversify an immune response. Some specificity is
determined within the Tlr family by the differential use of
adapter proteins; Myd88 dependant and independent signal-
ing events to some degree drive the recruitment of mitogen-
activated protein kinases (MAPK), interferon, and protein
kinase C pathways to the immune response [4,8,9]. Products
of the inflammatory cascade such as IL-1 and TNF-α further
amplify the inflammatory response [10].
From a genomic perspective, protein diversity is generated
through the use of alternate exons from a transcriptional
framework (TK) - on average three different proteins from
each TK [11]. Concomitantly, generation of variant proteins is
predicted to alter the signaling cascades that they participate
in. The role of alternate splicing in the innate immune system
is particularly interesting. It has been known for some time
that type-1 interferon signaling is modified by variations in
the type 1 interferon receptor (IFNAR)2. The short chain var-
iant and the soluble form act as dominant negative proteins,
modulating type I interferon responses [12-14]. The observa-
tion of dominant-negative variants of key Tlr signaling com-
ponents includes Myd88s [15] and Irak2 [16]. These proteins
are induced by Tlr signaling, and are necessary for resolution
of a Tlr-directed immune response. This suggests that alter-
nate splicing occurs in response to signal transduction path-
ways, and requires inducible recruitment of splice factors as
well as tissue-specific splicing regulators.
Distribution of signals across all microarray probes Figure 1
Distribution of signals across all microarray probes. The scatter plots 
show the distribution of signals from (a) junction and exon probes and (b) 
intron probes. The average signal of each probe (unstimulated bone-
marrow derived macrophages (BMMs) and BMMs subjected to seven 
hours of stimulation with lipopolysaccharide (+7 hrs LPS); x axis) was 
plotted against the normalized ratio of +7 hrs LPS/unstimulated BMMs (y 
axis). Color of squares indicate the signal intensities are above (black) or 
below (gray) the background threshold.
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Analysis of alternate splicing in the innate immune system
has thus far been done on gene-by-gene basis (for review, see
[17]). We surveyed the combined FANTOM3 fl-CDNA and
public expressed sequence tag data set and identified a suite
of novel transcripts predicted to alter signaling in the Tlr
pathway. This study evaluates the variation in proteins aris-
ing from these alternate splicing events using a systematic
bioinformatics approach; predicts the impact a variant pro-
tein will have on signal transduction in the Tlr signaling cas-
cade, and tests the expression of these novel proteins in a
model of inflammatory macrophage activation.
Results and discussion
Identification and validation of variant members of the 
Tlr signaling pathway
The FANTOM3 TK defined the start, end, and splice bounda-
ries of all of the variant transcripts arising from a gene [11].
Seventy TKs were identified as generating two or more pro-
tein variants, and a total of 256 proteins were consequently
associated with the Tlr pathway (an average of three protein
products/TK). Each framework was reviewed for variant pro-
tein domains in order to predict the functional properties of
those variants.
TKs were built for 106 members of the Tlr and c-Jun N-termi-
nal kinase/p38 Mapk pathways, identified from the Kyoto
Encyclopaedia of Genes and Genomes [18], plus additional
scaffolding proteins and factors known to be important in
macrophage biology [19]. The pathway members, TK identifi-
ers, protein domain, and variant transcript data are available
online [20].
The splicing array consisted of 1,717 oligonucleotide probes
representing alternate transcripts arising from 106 TK.
Probes were designed across splicing junctions as well as each
exon. A representative set of intron probes for each TK was
used as a negative control. Figure 1 shows the distribution of
signals from junction probes, exon probes, and intron con-
trols, demonstrating a high degree of signal specificity for the
junction and exon probes. Primary bone-marrow derived
macrophages (BMMs) were differentiated in the presence of
colony stimulating factor 1 (Csf1) and profiled before and
after exposure to the Gram-negative bacteria endotoxin
lipopolysaccharide (LPS). We detected most of the predicted
splice variants in either macrophage population (summarized
in Table 1). The majority (1,445 out of 1,717 probes) from all
106 TKs were reliably expressed by macrophages in the
unstimulated or LPS-activated state. Eighty-eight probes
from 26 TKs were significantly induced after LPS exposure (t
test, P < 0.05); as expected, these were primarily the inflam-
matory targets of Tlr signaling (and mediators of inflamma-
tion) such as chemokines and cytokines (TNF-α, ILs), as well
as receptors, signal transduction molecules, and transcrip-
tion factors. These data are consistent with the known inflam-
matory profiles of mouse macrophages after LPS exposure
[10]. Thirty-nine probes from 13 TKs were significantly
repressed (t test, P  < 0.05) by LPS/Tlr4 signaling; these
included transcript variants of receptors (Csf1r and Infar1),
adapters (Toll interacting protein (tollip)), kinases (Irak4,
Map3k1, Map3k7, Mapk8, Mapk14, phosphoinositide-3-
kinase (Pik3)cg), and transcription regulators (activating
transcription factor 2 (Atf2), DNA methyltransferase
(Dnmt)1, small ubiquitin-related modifier (Sumo)) and effec-
tor molecules (serpin peptidase inhibitor, clade b
(Serpinb3b)). These data concur with our previous arrays
using representative probes for inflammatory gene targets
[10].
A database with pathway map was built for ease of navigation
through the Tlr signaling cascade, with TK numbers linking to
a comparison of each transcript in the framework and a
Table 1
Summary of splicing microarray data: unstimulated macrophages versus macrophages subjected to seven hours of LPS stimulation
Expressed unstimulated 
macrophages
Expressed macrophages + 
7 hr LPS
Variants repressed by LPS/
Tlr4 (t test P < 0.05)
Variants induced by LPS/
Tlr4 (t test, P < 0.05)
Transcript framework 107 106 13 26
Total number of probes 1,404 1,376 39 88
Receptors 16 TK Csf1r, Ifnar1 Tlr3, Cd86, Clesf9
Adapters 13 TK Tollip Rac2
Signal transducers 30 TK Irak4, Map3k1, Map3k7, 
Mapk14, Pik3cg, Serpinb3b
Pde4a, Pik3cd, Tbk1
Transcription factors 29 TK Atf2, Dnmt1, Sumo Nfkbia, Nfkb1, Nfkb2, 
Ikbke, Irf1, Stat1, Stat2, 
Stat3, Sin3a
Inflammatory effectors 17 TK Serpinb3b Ccl3, Ccl4, Ccl5, Cxcl10, 
Cxcl9, Il12b, Il1b, Il6, 
Casp8, Tnf-α
The splicing array consisted of 1,717 oligonucleotide probes representing alternate transcripts arising from 108 TK. The experiment was repeated 
four times, with dye-swap. LPS, lipopolysaccharide; TK, transcriptional framework; Tlr, Toll-like receptor.R10.4 Genome Biology 2006,     Volume 7, Issue 2, Article R10       Wells et al. http://genomebiology.com/2006/7/2/R10
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Murine Tlr4 encodes two variant transcripts: exon structure and expression of variant transcripts in BMMs Figure 2
Murine Tlr4 encodes two variant transcripts: exon structure and expression of variant transcripts in BMMs. (a) Genome viewer tracks. Mouse Toll-like 
receptor Tlr4 maps to the minus strand of chromosome 4. Probe track indicates the exon junctions spanned by oligoprobes on the splicing array. Probe 
1C spans the junction between exons 1 and 2. 2A spans the junction between exons 2 and 3, and is unique to the full-length Tlr4 variant. 3A and 4C span 
exons 2-4 and 4-5, respectively. Both probes detect the variant Tlr4 transcript. Transcripts are shown by exon-boxed cartoon. Variant 1 is a full-length 
Tlr4 transcript, variant 2 skips exon 3 and so lacks the transmembrane and cytoplasmic domains. (b) Scatter plot shows the distribution of expression 
detected by each probe. The average signal of each probe (unstimulated bone-marrow derived macrophages (BMMs) and BMMs subjected to seven hours 
of stimulation with lipopolysaccharide (+7 hrs LPS); x axis) was plotted against the normalized ratio of +7 hrs LPS/unstimulated BMMs (y axis). Junction 
probes are indicated by a triangle; intronic or intergenic controls are indicated by open boxes; and exon probes are indicated by black circles. The 
microarray detects expression of both Tlr4 transcripts in unstimulated and +7 hr LPS stimulated BMMs, and demonstrates a higher level of expression of 
the full-length variant.
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Figure 3 (see legend on next page)
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dynamic interphase with the FANTOM3 database. The
genome viewer has been annotated with a gff track for each
splicing probe on the array. Functional predictions from this
data set are highlighted in the following sections, reviewing
the impact on each part of the Tlr pathway, from receptor, sig-
nal transduction, and effector molecules.
Alternate splicing impacts on receptor complexes
The genomic structure of the Tlr family in mice is character-
ized by a small number of exons (typically three), with the
open reading frame (ORF) contained in the last exon. Alter-
nate splicing of the 5'-untranslated region (UTR) is a common
feature of this family in mouse and human isoforms, and
arises from different transcriptional start sites (TSSs) as well
as the internal splicing of UTR exons. Tlr3 transcripts with
variable 5'-UTR were found to be differentially regulated on
the splicing arrays (Additional data file 3). Although the func-
tional significance of variable 5'-UTR length in this class of
receptors is not understood, the use of different TSSs implies
differential promoter usage and this, combined with modifi-
cations of UTR structure, presumably alters the stability and
translational efficiency of the mRNA.
Mouse Tlr4 (TK 104448) was the only member predicted to
express a variable protein (Figure 2). The canonical receptor
has three exons, with the ORF spanning exons 2 and 3, pro-
ducing a 3.8 kilobase (kb) transcript and 836 amino acid
transmembrane protein. The variant transcript (from RIKEN
clone 4631423H05) skips exon 3 and splices onto exons 4 and
5 approximately 90 kb downstream of exon 2. The 1.8 kb tran-
script is predicted to encode a 154 amino acid secreted pro-
tein. This product does not appear to be conserved in humans
at the transcript or genome level; human TLR4 has four
reported variants, all of which alter the length of the extracel-
lular leucine-rich repeat, although the functional significance
of this has not been tested.
B o t h  v a r i a n t s  o f  m o u s e  T l r 4  are inducible by interferon-γ
priming as well as LPS stimulation of primary mouse
macrophages. Figure 3 demonstrates expression of the 3.8
and 1.8 kb Tlr4 variants by Northern blot analysis, splicing
arrays, and quantitative real-time polymerase chain reaction
(PCR) in C57Bl/6J and BALB/c mice. We confirmed the exon
composition of the variants by designing primers that
spanned exons 2-3 (3.8 kb variant) or exons 2-4 (1.8 kb vari-
ant) and testing the expression of Tlr4 in two different mouse
strains - BALB/c and C57Bl6J - by quantitative real-time
PCR.
The outcome of Tlr signaling is modified by the presence of
interferon and Csf1 in the local environment. We therefore
also examined the receptors for Csf1 (Csf1R; TK 167944) and
the IFNAR subunits. Our computational pipeline successfully
detected the alternatively spliced products of IFNAR1 (TK
177219) and IFNAR2 (TK 108218) TK subunits, and their
expression was confirmed in the array dataset. These have
been functionally characterized as dominant-negative modu-
lators of the type I interferon response [12-14]. Similarly, a
number of variants of the Csf1r have been identified from the
FANTOM3 data set, including at least two that lack the cata-
lytic cytoplasmic domain, one of which is predicted to be
secreted by PSORT [21]. The expression of soluble receptors
provides a 'ligand sink' that attenuates the dosage of cytokine
available to local macrophages. Likewise, membrane tethered
but catalytically dead variants may alter the capacity of a cell
to respond to cytokines in the environment. This is important
in an inflammatory context because Csf1 and type I interfer-
ons have been shown to prime and exacerbate the inflamma-
tory response, and expression of dominant-negative
receptors may antagonize this process.
Alternate splicing of chaperones and adapters predicts 
variable scaffolds for signaling cascades
The most fundamentally conserved Tlr signaling pathway
requires recruitment of Myd88 to the receptor complex [3].
Splicing of Myd88 has previously been reported, generating a
short protein (Myd88s) that lacks the intermediate region
between the Tir domain (which interacts with the Tlr) and the
death domain (which interacts with downstream kinases).
Myd88s was shown to repress inflammatory signals normally
mediated through Myd88 [15].
Mice that lack Myd88 exhibit profound deficiencies in innate
immune responses [22], but these same studies demon-
strated that Myd88-independent signaling pathways were
also important for effective innate immune function. Several
Validation of expression of Tlr4 transcripts by Northern blot and quantitative real-time-PCR Figure 3 (see previous page)
Validation of expression of Tlr4 transcripts by Northern blot and quantitative real-time-PCR. The expression of Toll-like receptor Tlr4 transcripts is 
detected by Northern blot and quantitative real-time (qRT) polymerase chain reaction (PCR), and is regulated in mouse bone-marrow derived 
macrophages by interferon (IFN) and lipopolysaccharide (LPS). Primary BMMs from two mouse strains (BALB/c and C57Bl/6J) were prepared and 
maintained overnight in the presence or absence of Csf1 (1 × 104 U/ml) before stimulation with IFN-γ (500 pg/ml) or LPS (10 ng/ml). (a) qRT-PCR 
expression of full Tlr4 (left) and truncated variant (right). Both transcripts were detected at higher levels in BALB/c BMMs. The expression of the 
truncated variant was 10-fold lower than the full-length variant in both mouse strains. Delta CT values were calculated from three replicates and 
normalized to a HPRT control primer set. (b) The expression of Tlr4 mRNA from C57Bl6/J BMM was detected by Northern blot using a 32P-labeled 
probe encoding part of the leucine rich repeat (LRR) domain, common to both variant Tlr4 transcripts. The membrane was stripped and re-probed with 
18S ribosomal RNA as a loading control. The expression of both variants was induced by IFN and LPS. (c) SMART predictions of the protein domains 
found in the full-length (top) and truncated (bottom) Tlr4 transcripts. The variant transcript retains a signal peptide and leucine-rich domain, but it lacks 
the transmembrane and cytoplasmic domains.http://genomebiology.com/2006/7/2/R10 Genome Biology 2006,     Volume 7, Issue 2, Article R10       Wells et al. R10.7
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Figure 4 (see legend on next page)
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adapter proteins are known to associate directly with Tlr in a
Myd88-independent manner. These include Tollip; TIR
domain-containing adapter protein (Tirap); TIR-containing
adaptor molecule (Ticam)1 and Ticam2; JNK interacting pro-
tein (Jip)1, Jip2 and Jip3; and the rho family small GTP bind-
ing protein 1 (Rac1). We found variant transcripts for each of
these adapter molecules, and confirmed their expression in
naïve and LPS-activated macrophages on the splicing arrays.
We discovered transcript variants of Ticam1 (TK 222079) and
Ticam2 (also known as Tram; TK 84178), which are interme-
diates in the interferon-response pathways initiated by Tlr3,
Tlr4, and Tlr7. Ticam2 has an alternate TSS, resulting in a
variable 5'-UTR length. Ticam1 and Ticam2 have ORFs that
are encoded in the last exon of their respective frameworks,
but internal splice sites in exon 2 of Ticam1 result in four
alternate transcripts and two alternate proteins (Figure 4).
T h e  f u l l - l e n g t h  ( u n i n t e r r u p t e d  e x o n  2 )  t r a n s c r i p t  i s  7 3 2
amino acids long. Transcripts initiating in this exon are
spliced, and generate a 310 amino acid protein with a car-
boxyl-terminal truncation and containing only the TIR
domain and proline-rich motifs. The truncated variant was
expressed at lower levels (Figure 4c) than the full-length var-
iant, and we predict that this novel protein variant may act as
a dominant-negative in a similar manner to the truncated
Myd88s.
Mapks and phosphoinositide-3-kinases (Pik3s) are recruited
at several points in the Tlr signaling cascade. Jip3 is a Mapk-
interacting protein that interacts directly with Tlr4 [23];
likewise Rac1 has been shown to recruit Pik3 through an
interaction with Tlr2 [24]. Five variants of Jip1 and Jip3 have
previously been reported [25] in mouse; we identified a sixth
variant of each in the FANTOM3 dataset (Additional data file
1). Two variants of Rac1 have been reported in humans - iso-
form 1 is 192 amino acids and isoform 2 is 211 amino acids
long [26,27]; we identified their mouse equivalents in the
FANTOM3 data set. These scaffolding proteins function to
recruit different partners of a kinase cascade. Alternate splic-
ing of these adapter proteins has been shown by others to
alter the interaction between scaffold and kinase, and so alter
the interaction between kinases themselves and ultimately
the signaling outcomes of that cascade [27,28].
Alternate splicing modulates Iraks and their 
chaperones
The Irak family of receptor-associated kinases are important
mediators of Tlr and IL-1 receptor signaling. Four members
of the murine Irak family have been described, and functional
studies have demonstrated regulation of Irak signaling by
inhibitory isoforms. Two inhibitory splice variants of Irak1
have been functionally validated: Irak-s [29] and Irak1b [30].
Four splice variants of Irak2 have previously been reported,
two of which inhibit Tlr4 signaling [16]. Irak3 (also known as
Irak-m) is a dominant-negative member of the Irak family
that also plays an important role in the repression of Tlr4 sig-
naling [31]. Our data describe novel variants of Irak2 and
Irak4 that are also predicted to be inhibitory, and are
expressed in inflammatory macrophages, and further demon-
strate variants of the chaperone proteins Tollip and Pellino.
The Iraks are important early signaling intermediates in Tlr
and IL-1 cascades. We discovered novel isoforms of Irak2 (TK
181931) and Irak4 (TK 121381) in the FANTOM data set.
Irak2e is a novel 151 amino acid protein generated by
termination in a unique exon 4; the ORF retains only the
death domain. Four protein variants of Irak4 are predicted.
Irak4a is a 459 amino acid protein. Irak4b uses an alternate
terminating exon, which resulted in a 453 amino acid protein
with a variant amino-terminus. Irak4c, a 197 amino acid pro-
tein, terminated in exon 6 and retained only the death
domains. Irak4d was a similarly truncated 195 amino acid
protein resulting from cryptic splice site in exon 5. Irak4c and
Irak4d are predicted to be dominant-negative variants.
The FANTOM3 data set contains a novel 220 amino acid Tol-
lip (TK 151087) isoform generated from an alternate termi-
nating exon that lacks the amino-terminal CUE domain, as
illustrated in Figure 5. Tollip is a 274 amino acid protein that
interacts with the ubiquitination machinery through an
amino-terminal CUE domain, and has also been shown to
interact directly with Tlr2 and Tlr4. Tollip inhibits Irak sign-
aling by targeting it for ubiquitination [32]. This domain is
important for the interaction of Tollip with Tom1 and the
ubiquitination pathway [33], and so an amino-terminal trun-
cated variant was predicted to exacerbate inflammatory
signaling through Tlr and Irak pathways. Both protein encod-
Variant transcript analysis of murine TIR-containing adaptor molecule (TICAM)1 Figure 4 (see previous page)
Variant transcript analysis of murine TIR-containing adaptor molecule (TICAM)1. (a) Genomic arrangement of murine TIR-containing adaptor molecule 
(Ticam)1 on the minus strand of mouse chromosome 17. TC (cap-analysis gene expression (CAGE) tag clusters) indicate transcriptional start sites (TSSs) 
from CAGE data (indicated by arrows). Two Ticam1 transcripts initiate from alternate TSSs: variant 1 from the major TSS (81 CAGE tags) and variant 2 
from a cluster of CAGE tags between 54,549 K and 54,550 K. (b) The probe track indicates the exon junctions spanned by oligoprobes on the splicing 
array. Probe 8C spans exons 1-2, 7I lies in the region spliced between exons 1b and 2b, and 5S spans the intron/exon boundary of exon 2b. These probes 
are unique to variant 1. 6A spans the junction between exons 1b and 2b and is unique to variant 2. (c) Scatter plot shows the distribution of expression 
detected by each probe. The average signal of each probe (unstimulated bone-marrow derived macrophages (BMMs) and BMMs subjected to seven hours 
of stimulation with lipopolysaccharide (+7 hrs LPS); x axis) was plotted against the normalized ratio of +7 hrs LPS/unstimulated BMM (y axis). Junction 
probes are indicated by a triangle; intronic or intergenic controls are indicated by open boxes; and exon probes indicated by black squares. Both the full-
length open reading frame (isoform 1) and the spliced 310 amino acid protein (isoform 2) are detected on the splicing array. CAGE data and splicing array 
expression analysis indicates that the full-length variant is more abundant.http://genomebiology.com/2006/7/2/R10 Genome Biology 2006,     Volume 7, Issue 2, Article R10       Wells et al. R10.9
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Figure 5 (see legend on next page)
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ing isoforms were expressed by macrophages on the splicing
array. The full-length 274 amino acid isoform was slightly but
significantly repressed at seven hours of LPS treatment (fold
change, t test, P < 0.05).
Human Tollip is also highly alternatively spliced, generating
several coding and noncoding variants. The full-length
human Tollip is a 274 amino acid protein. Alternate usage of
exons 2 and 3 generate a noncoding RNA and a 213 amino
acid variant, respectively. Similarly, we detected two tran-
scripts with no obvious ORF expressed from the mouse Tollip
framework. One was from upstream exon 1A, which is
expressed approximately ten-fold less than the transcripts
originating from exon 1B. The second noncoding transcript
originated from exon 1B and spliced onto a cryptic splice
acceptor in intron 3, interrupting the ORF.
Pellino2 (Peli2, TK 104834) is a scaffolding protein that inter-
acts with Irak1 and Irak4. Three Peli2 isoforms are generated
from four transcript variants. Peli2a is an 438 amino acid pro-
tein; Peli2b is a 319 amino acid protein and is encoded by two
different transcripts: the first initiates at exon 1 but skips
exons 2 and 3, and the second initiates at exon 3b (unique to
this variant). Peli2c is an amino-terminal truncated 155
amino acid protein that initiates at exon 1 and terminates at
exon 3a (unique to this transcript), and is lacking the Pellino
domain. All three variants are detected in macrophages on
the splicing array, and by cap-analysis gene expression
(CAGE) tag analysis. Strelow and colleagues [34] first
characterized Peli2, and identified several protein variants by
western analysis, including one lacking the amino terminus,
but these were assumed to be post-translational modifica-
tions of Peli mediated by Irak. Our data indicate that this
truncated peptide is most likely Peli2c, generated by alternate
splicing of the Peli2 TK, and generating a dominant-negative
protein that lacks the Pellino domain.
These data demonstrate further regulation of Irak signaling,
indicating that this is tightly controlled at a transcriptional
level by the production of numerous dominant negative iso-
forms, as well as chaperones that are predicted to alter the
location and association of Irak and its targets.
Alternate splicing of the Mapk and Pik3 pathways alter 
inflammatory signaling in macrophages
The Kyoto Encyclopaedia of Genes and Genomes identified
30 kinases that intersected the Tlr pathway, from which we
predicted that alternate transcription generated total of 72
novel kinases available to Tlr signaling in macrophages. The
Mapk and Pik3 pathways in particular are integral to Myd88
dependant and independent signaling outcomes. The Mapk
cascade diversifies inflammatory signaling, whereas Pik3 is
thought to temper the severity of the acute signal from Tlr (for
review, see [35]).
Mapk14/p38 (TK 106167) is emerging as an important mod-
ulator of macrophage signaling in response to a diverse set of
PAMPs. Three protein variants of p38 have been described to
date: isoforms 1 and 3 are 359 amino acid proteins with the
variable inclusion of exon 10 (isoform 1) or exon 11 (isoform
3). Human EXIP (mouse piccolo), the carboxyl-terminally
truncated Mapk14 258 amino acid variant, has been shown to
interact directly with TOLLIP and Irak to downregulate sign-
aling [36]. Our data predicted a fourth, amino-terminally
truncated Mapk14 283 amino acid variant initiated from a
novel exon 1B, and confirmed the expression of isoforms 1, 3,
and 4 in macrophages. Figure 6 demonstrates the complex
transcription arising from the Mapk14 TK, and profiling indi-
cated that expression of Mapk14 variants is differentially reg-
ulated, with isoforms 1 and 3 repressed by LPS exposure of
mouse macrophages.
Mapk14 is central to inflammatory signaling, and the func-
tional validation of variants of the Mapk14 framework illus-
trates the potential for regulation of signal transduction by
other Mapk and Pik3 variants. We overexpressed isoforms 1
and 3 of Mapk14 in RAW264.7 cells to evaluate the impact of
these proteins on inflammatory activation and survival of
macrophages (Figure 7). Overexpression of isoform 3 led to
an overtly activated macrophage phenotype even in unstimu-
lated cells, whereas over-expression of isoform 1 did not
change the morphology of the RAW cells. The survival of
RAW264.7 cells exposed to LPS was modified by over-expres-
sio n of  both  v ar ian ts  (F igu r e  7b) ; h o we ve r , w e n ote d th a t
over-expression of isoform 3 led to cell cycle arrest in
RAW264.7 prior to LPS exposure.
Variant transcript analysis of murine Toll interacting protein (Tollip) Figure 5 (see previous page)
Variant transcript analysis of murine Toll interacting protein (Tollip). (a) Genomic arrangement of murine Toll interacting protein (Tollip) on the minus 
strand of mouse chromosome 7. TC (cap-analysis gene expression (CAGE) tag clusters) indicate two transcriptional start sites (TSSs): variants 1, 2 and 4 
are from the major TSS at 129,607 K and variant 3 is from a cluster of CAGE tags (indicated by arrows) at 129,623 K. (b) The probe track indicates the 
exon junctions spanned by oligoprobes on the splicing array. Variant transcripts are indicated by boxed exon cartoon. Variant 1 is a 274 amino acid protein 
initiating from exon 1B. Variant 2 is a 220 amino acid dominant-negative protein that skips exon 6 and so lacks the carboxyl-terminal CUE domain. Variant 
3 initiates from exon 1A and lacks an open reading frame (ORF). Variant 4 contains a cryptic splice acceptor in intron 3 that disrupts the ORF, resulting in 
a noncoding transcript. (c) Scatter plot shows the distribution of expression detected by each probe. The average signal of each probe (unstimulated 
bone-marrow derived macrophages (BMMs) and BMMs subjected to seven hours of stimulation with lipopolysaccharide (+7 hrs LPS); x axis) was plotted 
against the normalized ratio of +7 hrs LPS/unstimulated BMM (y axis). Junction probes are indicated by a triangle and exon probes are indicated by black 
squares. Probe 1A measured the expression of the alternate terminating exon associated with variant 2. Probes 7A and 8A measured the expression of 
variants 3 and 4, respectively. Probe 6A (variant 1) was significantly repressed after LPS treatment (P < 0.05).http://genomebiology.com/2006/7/2/R10 Genome Biology 2006,     Volume 7, Issue 2, Article R10       Wells et al. R10.11
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Figure 6 (see legend on next page)
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Signal transduction in the Tlr cascade has great potential to
be similarly regulated at a genomic level through variation in
other kinases. Of the 72 variant proteins generated from the
30 Mapk and Pik3 TKs examined here, 15 were predicted to
generate dominant-negative isoforms (Additional data file 1),
and it is a reasonable supposition that a significant propor-
tion of these will act competitively to alter inflammatory sig-
naling and macrophage differentiation/survival.
Alternate splicing generates a large cohort of 
transcription factors and chromatin modifiers
Signal transduction by Tlr receptors culminates in the activity
of nuclear factor-κB (via Irak/Traf6), Ap-1/Erk/Elk (via
Mapk), Irf (via Ticam) and Stat (via Ifnar) [37]. Thirteen tran-
scriptional regulators, including Ikbkb, Ikbke and Ikbkg,
were predicted to generate 49 variant proteins. The Atf2
framework alone generated 18 variants.
We identified a number of novel Stat isoforms in the FAN-
TOM data set, including four Stat1 isoforms (TK100600), two
Stat2 (TK 98057) isoforms, and three Stat3 isoforms (TK
108218). Each of these frameworks had variant transcripts
induced by LPS-stimulation of macrophages, as measured on
the splicing arrays. The data for Stat1 are shown in Figure 8.
Stat1 is known to produce alpha (749 amino acid) and beta
(712 amino acid) isoforms in human and mouse [38]. Two
novel isoforms are predicted in the FANTOM3 dataset - a 755
amino acid and a 177 amino acid isoform. CAGE tag analysis
(Figure 8a) of the Stat1 promoter indicated that the novel 755
amino acid isoform initiation at exon 1B was most highly
expressed in adipocytes, and infrequently used by macro-
phages. This variant inserts an additional 6 amino acids
(VFVPFQ) in the DNA binding domain by using cryptic splice
site upstream of exon 17, and indeed this probe was detecta-
ble but not highly expressed in the macrophage populations
screened on the splicing arrays (Figure 8).
Three of the four Stat1 isoforms were expressed in macro-
phages, and one of these - Stat1a - was differentially regulated
by seven hours of exposure to LPS. Figure 8 shows data from
the splicing arrays that indicated differential expression of
Stat1 isoforms after LPS challenge of macrophages. Junction
probes spanning alternate (A) and constitutive (C) exons 6-7
(probe11A), 6-8 (probe 12A), and 7-8 (probe 13A; Figure 7)
showed that the 177 amino acid isoform lacking exon 7 was
highly expressed in macrophages, but was not regulated at
seven hours by Tlr4/LPS signaling. This isoform lacks the
DNA binding and SH domains, retaining just the first STAT
domain, and is predicted to be a dominant-negative protein.
The array data indicate that mRNA of the alpha but not the
beta isoform is LPS/Tlr4 induced. The isoforms containing
exon 7 and most of the constitutive exons were induced by
LPS (t test, P < 0.05). The terminating exon probe for the beta
isoform was highly but not differentially expressed at seven
hours of LPS treatment, whereas the probes unique to the
alpha isoform were expressed at a lower level, but the expres-
sion of these was higher in the LPS stimulated state.
Macrophages respond rapidly at a transcriptional level to
PAMPs, and this occurs at the level of chromatin remodeling
as well as transcription factor binding. Several chromatin
modifiers, histone deacetylases (Hdac), MYST histone acetyl-
transferases (Myst), DNA methyltransferases (Dnmt), and
the small ubiquitin-related modifiers (Sumo) were found to
generate a large number of alternatively transcribed prod-
ucts. Interestingly, although macrophages expressed most of
these variants, isoforms of Dnmt1 and Sumo were downregu-
lated by LPS signaling.
Conclusion
The impact of alternate transcription on innate immune sign-
aling has been hinted at by several studies on individual dom-
inant-negative variants of key signaling molecules, including
Ifnar2, Myd88, and Irak1 and 2 [14-16,29]. We have surveyed
the transcripts arising from TKs for 107 members of the Tlr
signaling pathway in mouse, and propose that the production
of protein variants in general, and of dominant-negative
proteins in particular, is a widespread mechanism for the reg-
ulation of inflammation.
The complexity of alternate splicing per TK increased as we
progressed from receptor complex to transcriptional regula-
tor. The Tlr receptors were typically encoded from a single
exon ORF, arguing that diversification of this receptor family
Murine Mapk14/p38-α encodes four variant proteins: exon structure and expression in BMMs Figure 6 (see previous page)
Murine Mapk14/p38-α encodes four variant proteins: exon structure and expression in BMMs. (a) Genomic arrangement of murine mitogen-activated 
protein kinase (Mapk)14 on the plus strand of mouse chromosome 17. The probe track indicates the exon junctions spanned by oligoprobes on the 
splicing array. (b) Variant transcripts are indicated by boxed exon cartoon. Variants 1 and 3 are 359 amino acid proteins that alternate exon 10 (variant 1) 
or exon 11 (variant 3). Piccolo (variant 2) is a 258 amino acid dominant-negative isoform. Variant 4 originates from a novel transcription start site (TSS) 
with a predicted 283 amino acid open reading frame (ORF) lacking the ATP-domain. Variant 5 included a novel exon that interrupts the ORF. (c) Scatter 
plot shows the distribution of expression detected by each probe. The average signal of each probe (unstimulated bone-marrow derived macrophages 
(BMMs) and BMMs subjected to seven hours of stimulation with lipopolysaccharide (+7 hrs LPS); x axis) was plotted against the normalized ratio of +7 hrs 
LPS/unstimulated BMM (y axis). Open triangles indicate constitutive junction probes, black triangles indicate alternate junction probes, and exon probes 
are indicated by black squares. Probe 3A measures the inducible expression of variant 4 after LPS treatment (P < 0.05). Probes 13A and 15EOL measure 
the expression of variant 2 (piccolo), which was low compared with variant 1 or 4 (measured by probe 14A). Probe 12A confirms a low expression of 
variant 3 in macrophages.http://genomebiology.com/2006/7/2/R10 Genome Biology 2006,     Volume 7, Issue 2, Article R10       Wells et al. R10.13
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Mapk14/p38-α isoforms differentially alter macrophage survival Figure 7
Mapk14/p38-α isoforms differentially alter macrophage survival. Raw264.7 cells were transfected with (a) pef6 vector only, (b) mitogen-activated protein 
kinase (Mapk)14 variant 1, and (c) Mapk14 variant 3. Each panel illustrates the transfectants before (left panels) and after (right panels) 6 hours of exposure 
to lipopolysaccharide (LPS; 10 ng/ml). Fluorescence activated cell sorting (FACS) analysis showed the percentage of cells in each stage of the cell cycle: 
apoptosis (A), G1, S, and G2 phases. The FACS findings in panel a were as follows: unstimulated pef6 control - A 2.4, G1 69, S 17.6, and G2 10.9; and +LPS - 
A 3.1, G1 78.6, S 9.2, and G2 9.4. In (b) the FACS findings show that Mapk14 isoform 1 lowered inflammatory cell survival: FACS before - A 3.5, G1 74, S 12, 
and G2 10.6; and +LPS - A 20.5, G1 59.5, S 12, and G2 8.2. In (c) the FACS findings show that Mapk14 isoform 3 over-expression alters cell survival in 
unstimulated and inflammatory cells: FACS before - A 9, G1 65, S 8, and G2 18; and +LPS - A 32.5, G1 47.5, S 7, and G2 13.
(a)  Pef6 control
(b)  Variant 1
6 hours     S P L + d e t a l u m i t s n U
(c)  Variant 3R10.14 Genome Biology 2006,     Volume 7, Issue 2, Article R10       Wells et al. http://genomebiology.com/2006/7/2/R10
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has occurred through gene expansion rather than alternate
splicing of protein products. The exception was Tlr4, for
which we described a novel transcript predicted to encode a
secreted Tlr4 isoform. Downregulation of the Tlr4 receptor
complex by soluble CD14 (produced from a post-translational
cleavage) has been demonstrated, as well as interactions with
Tlr1 and Rp105 [39]. Further analysis of the 1.8 kb variant is
necessary to determine whether alternate splicing of Tlr4
itself adds another inhibitory mechanism to the Tlr4 receptor
complex. We found that at least nine of the adapter molecules
and 16 of the kinases in this pathway alone produced multi-
ple, variant protein products through alternate splicing. Of
these, we demonstrated the proapoptotic effects of Mapk14
variants on LPS-stimulated macrophages. Alternate tran-
scription of chromatin remodeling complexes and transcrip-
tion factors could generate a large number of variant proteins,
and the expression of these variants was regulated by LPS/Tlr
signaling. The inflammatory effector molecules released by
Tlr signaling - interleukins, chemokines and cytokines - act to
amplify rapidly the inflammatory signal, by recruiting and
priming immune cells. As the repertoire of signaling mole-
cules increased at each step in the Tlr cascade, we propose a
concomitant increase in the repertoire of signaling events.
Importantly, the expression of dominant-negative proteins
for many key signaling molecules provides the immune sys-
tem with opportunities to resolve inflammation.
A healthy innate immune system has the capacity to generate
a broad repertoire of responses to combat infectious disease.
Alternate transcription of Tlr pathways is just one mechanism
of generating a combinatorial expansion of possible signaling
outcomes, including repression of signaling at multiple points
in the cascade. Why are so many points of control necessary?
The flip side to these inflammatory pathways is susceptibility
to inflammatory diseases. Uncontrolled inflammation leads
to tissue damage and sepsis in an acute infection, and the Tlr
signaling cascades have been linked to chronic inflammatory
diseases such as atherosclerosis, arthritis, and pulmonary
diseases. The role of variant signaling proteins in the patho-
genesis of these diseases is yet to be explored; this study indi-
cates that they are likely to provide new ways to target the
inflammatory process.
Materials and methods
Transcript framework assembly and splicing 
predictions
The computation pipeline has been described in detail else-
where [11]. Briefly, alternate transcript and peptide predic-
tions were collected from the FANTOM3 and public data sets.
Transcript frameworks of starts, ends, and exon boundaries
were compiled for each cluster of transcripts. Domain predic-
tions from InterPro for each alternate transcript were
mapped to genomic location and are available as gff tracks
(Additional data file 2). Predictions of membrane topology
and presence of a signal peptide were generated using PHO-
BIUS [40], and those predicted as containing a signal peptide
were analysed using PSORTII [21]. Gff tracks for splicing
array probes and CAGE tissue expression have been made
available to support the expression analysis.
Splicing array expression profiling
Custom oligonucleotide microarrays were obtained from
Combimatrix Corp (Mukilteo, WA, USA). The probes were
designed by the manufacturer's automated pipeline to a
length of 36 bases with 18 bases either side of the splice site.
Probes were also designed manually for control genes with
l e n g t h s  r a n g i n g  f r o m  3 5  a n d  4 0  b a s e s .  A l l  p r o b e s  w e r e
designed as antisense probes, for detection of directly labeled
mRNA.
In situ synthesized oligonucleotide arrays (Combimatrix
Corp.) were designed to screen the expression of alternate
transcription from these frameworks. The splicing array con-
sisted of 1,717 oligonucleotide probes representing alternate
transcripts arising from 106 TK. Probes were designed across
splicing junctions, as well as each exon. A representative set
of intron probes for each TK were used as negative controls.
Figure 1 shows the distribution of signals from junction
probes, exon probes, and intron controls, demonstrating a
high degree of signal specificity for the junction and exon
probes. Primary BMMs were differentiated in the presence of
Csf1 and profiled before and after exposure to the Gram-neg-
ative bacteria endotoxin LPS.
Untreated and LPS treated (seven hours) primary BMMs
were prepared as previously described [10]. RNA was
extracted using QIAGEN RNeasy (for total RNA) followed
Murine Stat1 encodes four variant proteins: exon structure and expression of variant transcripts in BMMs Figure 8 (see following page)
Murine Stat1 encodes four variant proteins: exon structure and expression of variant transcripts in BMMs. (a) Genomic arrangement of murine Stat1 on 
the plus strand of mouse chromosome 1. Probe track indicates the exon junctions spanned by oligoprobes on the splicing array. (b) Variant transcripts are 
indicated by boxed exon cartoon. Stat1a is a 749 amino acid protein initiating from exon 1A. Stat1b is 712 amino acids, terminates at exon 23, truncating 
carboxyl-terminal 37 amino acids. Isoform c is 755 amino acids with alternate initiation at exon 1B (open box), and the insertion of an additional 6 amino 
acids (VFVPFQ) in the DNA binding domain by using cryptic splice site upstream of exon 17 (grey exon box). Isoform d is a 177 amino acid protein that 
skips exon 7 and terminates at exon 9. There are at least four noncoding transcripts observed, initiating from exons 1, 19, and 22 (not shown). (c) Scatter 
plot shows the distribution of expression detected by each probe. The average signal of each probe (unstimulated bone-marrow derived macrophages 
(BMMs) and BMMs subjected to seven hours of stimulation with lipopolysaccharide (+7 hrs LPS); x axis) was plotted against the normalized ratio of +7 hrs 
LPS/unstimulated BMM (y axis). Triangles indicate junction probes and exon probes are indicated by black squares. Differential expression was determined 
using a t test cutoff of P < 0.05.http://genomebiology.com/2006/7/2/R10 Genome Biology 2006,     Volume 7, Issue 2, Article R10       Wells et al. R10.15
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Figure 8 (see legend on previous page)
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QIAGEN oligotex resin (QIAGEN, Hilden, Germany). Two
milligrams of polyA+ RNA was labelled directly with Cy3 or
Cy5 using the Kreatech ULS labelling system (Kreatech Bio-
technology, Amsterdam, Netherlands). Four pair-wise com-
parisons were performed, with a dye swap included for half of
the experiments. Overnight hybridizations and data
extraction was performed in accordance with the manufac-
turer's instructions. All data was Lowess normalized and vis-
ualized using Genespring7.2 (Silicon Genetics Inc., Agilent
Technologies, Palo Alto, CA, USA). All expression data are
available via GEO (accession number: GSE4044) or can be
visualized via IMB Signet (Silicon Genetics Inc.) [41].
Northern analysis
RNA samples were electrophoresed using denaturing formal-
dehyde agarose gels. Samples contained 20 µg RNA in 1 ×
MOPS (3-(N-morpholino)-propanesulfonic acid), 5.9%
(weight/vol) formaldehyde, and 50% deionized formamide.
An RNA marker (0.24-9.5 kb RNA ladder; Invitrogen,
Carlsbad, CA, USA) was prepared, electrophoresed, and
detected according to manufacturer's instructions for approx-
imate size determination of RNA bands. The probe used for
mouse  tlr4  mRNA detection was amplified by PCR, and
encoded part of the leucine-rich repeat domain (forward: 5'-
AGAGAATCTGGTGGCTGTGG-3'; reverse: 5'-TCAACCGAT-
GGACGTGTAAA-3'). The labeled probe was boiled for 5
minutes at 100°C before hybridization. 18S ribosomal RNA
was detected using the oligonucleotide probe 5'-CATGGTAG-
GCACGGCGACTACCAT-3', as reported previously [42].
Real-time PCR
cDNA levels of all genes and the internal control gene, murine
hypoxanthine-guanine phosphoribosyl transferase (hprt),
were estimated by quantitative PCR with the SYBR Green kit
(Applied Biosystems, Foster City, CA, USA), gene-specific
primers and an ABI Prism 7000 Sequence Detection System
(Applied Biosystems). Threshold cycle values were calculated
from amplification plots and gene expression was expressed
relative to the control gene hprt. Gene-specific primer pairs
were designed using Primer3 software [43,44]. Primers used
were as follows: Tlr4 exon 2F tctgagcttcaaccccttg, Tlr4 exon
3R tgccatgccttgtcttca, and Tlr4 exon 4R gcctcggaggatttggat.
Additional data files
The following additional data are included with the online
version of this article: A csv file showing each transcript vari-
ant for the Tlr pathway, the splicing array probe sequences,
and their genomic coordinates (Additional data file 1); a gff
track of each splicing array probe for annotation of genome
viewers (Additional data file 2); a text file showing all of the
raw data from the four replica splicing array experiments
(Additional data file 3); and a text file showing the Tlr data-
base data, which may also be visualized and searched from
our macrophages website [44] (these data include the full
analysis of each predicted variant protein and links to a
genome viewer with probe tracks overlayed as gff; Additional
data file 4).
Additional File 1 A csv file showing each transcript variant for the Tlr pathway A csv file showing each transcript variant for the Tlr pathway, the  splicing array probe sequences, and their genomic coordinates. Click here for file Additional File 2 A gff track of each splicing array probe for annotation of genome  viewers A gff track of each splicing array probe for annotation of genome  viewers. Click here for file Additional File 3 A text file showing all of the raw data from the four replica splicing  array experiments A text file showing all of the raw data from the four replica splicing  array experiments. Click here for file Additional File 4 A text file showing the Tlr database data A text file showing the Tlr database data, which may also be visual- ized and searched from our macrophages website [44] (these data  include the full analysis of each predicted variant protein and links  to a genome viewer with probe tracks overlayed as gff). Click here for file
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